

REIG JOFRE UPGRADES ITS RATING TO "VERY GOOD" IN THE 2014 PROFARMA PROGRAM

- The Profarma program is an initiative of the Ministry of Industry, Energy and Tourism (MINETUR), which aims to enhance the competitiveness of the pharmaceutical sector, strengthening those activities with higher added value, such as R&D and new production technologies.
- In addition to the prestige of this qualification, it is an important argument to attract new investments.

Barcelona (Spain), May 6, 2015. The pharmaceutical company Reig Jofre was rated "Very good" in the call 2014 of Profarma program, whose resolution was published on the website of the Ministry of Industry, Energy and Tourism last April 29, 2015. In this last call, Reig Jofre improved the qualification achieved in 2013, when it was granted "Good".

Profarma is a joint program of the Ministry of Industry, Energy and Tourism, the Ministry of Economy and Competitiveness and the Ministry of Health, Social Services and Equality. It aims to encourage the sector's competitiveness, enhancing activities that bring higher added value, such as investment in new industrial plants and production technologies, and promoting research, development and innovation.

Companies are both classified and qualified in a number of groups and categories according to their excellence in different industrial, economic and R&D&i aspects. Reig Jofre is in category A, which includes pharma companies with own production plants and research centers, which are qualified as "excellent" , "very good", "good" and "acceptable".

The Ministry of Industry, Energy and Tourism assessed a total of 55 applications, and only Reig Jofre was incorporated as a new company in this category, sharing this classification with Boehringer Ingelheim, GP Pharm, Invent Farma, Laboratorios Salvat, Laboratorios Servier, Merck and Tigenix.



Besides the prestige implied by these ratings, they are considered to constitute a source of relevant information when applying for state support in programs related to the industrial policy of the Ministry of Industry, Energy and Tourism, as well as the support policy to R&D&i of the Ministry of Economy and Competitiveness.

According to Ignasi Biosca, CEO of Reig Jofre, *"this recognition is, primarily, the result of an intense commitment to R&D&i and in specialized production capacity, two of Reig Jofre's pillars since its inception and in which the company strengthens its investment year after year."*

About Reig Jofre

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the development, manufacture and marketing of own products (approximately 78% of sales) and one of specialized manufacturing for thirds (22% of sales). At its core activity, the company specializes in the development of prescription and non-prescription pharmaceutical products, injectable generics based on specialized technologies, medical devices, food supplements and cosmetics. The company directs its R&D to develop new indications and/or dosage forms of known active principles, generic medicines with a special focus on beta lactam and lyophilized injectable antibiotics, topical dermatological products, OTCs and food supplements as well as the development of new innovative molecules in partnership with start-ups and research centers.

Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Total outstanding shares: 1,264,284,408

For further information

Media

Ricardo Franco
ATREVIA
Tel. +34 93 419 06 30
rfranco@atrevia.es

Investors and analysts

Gloria Folch
Head of Investor Relations
REIG JOFRE
Tel. +34 93 584 81 85
gloria.folch@reigjofre.com